Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 189

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*

Wiedermann, Christian J., Hoffmann, Johannes N., Juers, Mathias, Ostermann, Helmut, Kienast, Joachim, Briegel, Josef, Strauss, Richard, Keinecke, Heinz-Otto, Warren, Brian L., Opal, Steven M. · 2006 · Critical Care Medicine

Abstract

OBJECTIVE: To explore if patients with severe sepsis and with a predicted high risk of death (according to the Simplified Acute Physiology Score II) might have a treatment benefit from high-dose antithrombin III. DESIGN: Subgroup analysis of a randomized, placebo-controlled, double-blind, prospective phase III study. SETTING: Unifactorial and multifactorial reanalysis of prospectively defined populations from the KyberSept trial. PATIENTS: We studied 1,008 patients (43.6% of the overall intention-to-treat population, n = 2,314) with a predicted mortality rate of 30-60% at study entry as defined by the Simplified Acute Physiology Score II. INTERVENTIONS: Patients were randomized in a 1:1 fashion to receive either high-dose antithrombin III (30,000 IU intravenously over the period of 4 days) or placebo. MEASUREMENTS AND MAIN RESULTS: In a Kaplan-Meier analysis of patients with a predicted mortality of 30-60%, the survival time when followed up for 90 days after admission was increased in the high-dose antithrombin III group compared with placebo (p = .04). If heparin was avoided during the 4-day treatment phase with high-dose antithrombin III (n = 140) or placebo (n = 162), the treatment effect appeared to be even more pronounced: 28-day mortality rate, 35.7% vs. 44.4% (risk ratio, 0.804; 95% confidence interval, 0.607-1.064); 56-day mortality rate, 39.9% vs. 52.2% (risk ratio, 0.764; 95% confidence interval, 0.593-0.984); 90-day mortality rate, 42.8% vs. 55.1% (risk ratio, 0.776; 95% confidence interval, 0.614-0.986). Like in the overall population, the percentage with any bleeding was increased in patients receiving high-dose antithrombin III compared with placebo. Survival rates were in favor of high-dose antithrombin III in patients both with and without bleeding complications. CONCLUSIONS: Treatment with high-dose antithrombin III may increase survival time up to 90 days in patients with severe sepsis and high risk of death. This benefit may even be stronger when concomitant heparin is avoided.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.ccm.0000194731.08896.99

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 189

Metadata

Authors
Wiedermann, C. J., Hoffmann, J. N., Juers, M., Ostermann, H., Kienast, J., Briegel, J., Strauss, R., Keinecke, H.-O., Warren, B. L., & Opal, S. M.
Venue
Critical Care Medicine
Published
2006-02
Volume
34
Issue
2
Pages
285-292
ISSN
0090-3493 (ISSN-L)
OpenAlex
W2048933053
Cited by
189
References
1
FWCI
15.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*. https://app.cochat.ai/papers/10.1097/01.ccm.0000194731.08896.99
The paper
Wiedermann, C. J., Hoffmann, J. N., Juers, M., Ostermann, H., Kienast, J., Briegel, J., Strauss, R., Keinecke, H.-O., Warren, B. L., & Opal, S. M. (2006). High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*. Critical Care Medicine. https://doi.org/10.1097/01.ccm.0000194731.08896.99

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.